Second, the constraints of covariates (key cardiovascular metabolic drugs, especially newer drugs such as GLP-1 receptor agonists and SGLT2 inhibitors), may simultaneously affect CMI and OSA. The gene discussed is GLP1R; the disease is obstructive sleep apnea syndrome.